Document Detail


Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
MedLine Citation:
PMID:  19441109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.
Authors:
Gautam Borthakur; E Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Hagop Kantarjian
Related Documents :
6932649 - Defibrination in adult acute lymphoblastic leukaemia. report of four cases.
6118669 - Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute l...
6192899 - Red cell aplasia in myelofibrosis with myeloid metaplasia. a distinct functional and cl...
8722369 - Polymerase chain reaction is highly predictive of relapse in patients following t cell-...
2293879 - Results of chromosome studies and their relation to morphology, course, and prognosis i...
2673329 - Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations.
2884999 - Partial deficiency of subunits in complex i or iv of patients with mitochondrial myopat...
19144299 - Immunologic evaluation of patients with recurrent ear, nose, and throat infections.
23140269 - The inflammatory biomarker ykl-40 at admission is a strong predictor of overall mortality.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer     Volume:  115     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-10     Completed Date:  2009-08-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3217-21     Citation Subset:  AIM; IM    
Affiliation:
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. gborthak@mdanderson.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Core Binding Factors / metabolism*
Cytarabine / therapeutic use
Disease-Free Survival
Female
Humans
Leukemia, Myeloid, Acute / drug therapy,  genetics,  mortality*
Male
Middle Aged
Neoplasms, Second Primary / mortality*
Survival Analysis
Translocation, Genetic
Chemical
Reg. No./Substance:
0/Core Binding Factors; 147-94-4/Cytarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in hu...
Next Document:  Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung can...